TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06155487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AJH-2947 100 mg (SAD)
Description: Oral Tablet, Single dose of AJH-2947 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Tablet, Single dose of Placebo 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AJH-2947 200 mg (SAD)
Description: Oral Tablet, Single dose of AJH-2947 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Tablet, Single dose of Placebo 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AJH-2947 300 mg (SAD)
Description: Oral Tablet, Single dose of AJH-2947 300 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Tablet, Single dose of Placebo 300 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AJH-2947 400 mg (SAD)
Description: Oral Tablet, Single dose of AJH-2947 400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Tablet, Single dose of Placebo 400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AJH-2947 600 mg (SAD)
Description: Oral Tablet, Single dose of AJH-2947 600 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Tablet,Single dose of Placebo 600 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AJH-2947 800 mg (SAD)
Description: Oral Tablet, Single dose of AJH-2947 800 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Tablet, Single dose of Placebo 800 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AJH-2947 200 mg (MAD)
Description: Oral Tablet, Multiple (once daily for 7days) oral dose of AJH-2947 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Tablet, Multiple (once daily for 7days) oral dose of Placebo 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AJH-2947 400 mg (MAD)
Description: Oral Tablet,Multiple (once daily for 7days) oral dose of AJH-2947 400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Tablet, Multiple (once daily for 7days) oral dose of Placebo 400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AJH-2947 600 mg (MAD)
Description: Oral Tablet, Multiple (once daily for 7days) oral dose of AJH-2947 600 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Tablet, Multiple (once daily for 7days) oral dose of Placebo 600 mg
Study: NCT06551116

Intervention type: DIAGNOSTIC_TEST
Intervention: CE-10-IVD
Description: Leftover tumor tissue from a routine biopsy will be sent for analysis.
Study: NCT06575985

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat acclimation and exercise training
Description: 10-day intervention consisting of daily 60-min exercise sessions aimed to induce increases in core body temperature, conducted in a climactic chamber set to 35°C and 50% relative humidity.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Thermo-neutral exercise training group
Description: 10-day intervention consisting of daily 60-min exercise sessions conducted in a climactic chamber set to 23°C and 50% relative humidity.
Study: NCT06575062

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct Pulp Capping with ProRoot MTA
Description: In this intervention, following the removal of carious dentin, the pulp tissue is directly exposed. ProRoot MTA is carefully applied over the exposed pulp to create a protective barrier. The material is mixed according to the manufacturer's instructions and placed directly onto the pulp exposure site. A light pressure is applied to ensure a good adaptation of the material. MTA was covered with resin-modified glass ionomer cement. Restoration was completed using composite resin.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulpotomy with ProRoot MTA
Description: In this procedure, after the removal of the coronal pulp tissue, ProRoot MTA is applied over the exposed root canal orifices. The MTA is mixed according to the manufacturer's instructions and placed in the pulp chamber to cover the root canal entrances. The material is carefully adapted to create a seal that prevents bacterial contamination and promotes tissue healing. MTA was covered with resin-modified glass ionomer cement. Restoration was completed using composite resin.
Study: NCT05984940

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ortho MTA cement
Description: Ortho MTA has a fine granularity for only 2 microns. It penetrates into dental tubules and fuses itself to the surface where it is applied. In addition, it prevents micro-leakage by forming an interfacing layer of hydroxyapatite (Hap) between the OrthoMTA and the canal wall.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GP and AH Plus sealer
Description: AH Plus Sealer is a calcium silicate-based root canal sealer. Tricalcium Silicate interacts with body fluids to release calcium and hydroxide ions that promote hydroxyapatite (HA) formation.
Study: NCT06576635

Intervention type: DRUG
Group type: OTHER
Intervention: Docetaxel
Description: 75 mg/m2 IV over 1-hour Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: OTHER
Intervention: Paclitaxel
Description: 135 mg/m2 IV over 3 hours Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: OTHER
Intervention: Gemcitabine
Description: 1000 mg/m2 or 1250 mg/m2 IV over 30 min Days 1, 8, and 15 of each 28-day cycle or Days 1 and 8 of each 21-day cycle 28 days (1000mg/m2 cohort)~21 days (1250mg/m2 cohort)

Intervention type: DRUG
Group type: OTHER
Intervention: Pemetrexed
Description: 500 mg/m2 IV over 10 minutes Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: OTHER
Intervention: Vinorelbine
Description: 30 mg/m2 IV through a weekly injection over 6-19 minutes Days 1, 8, and 15 of each 21-day cycle
Study: NCT04917822

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotion regulation
Description: Emotion regulation arm will provide the parents and children with four 2-hour weekly sessions. For the parents, the main topics include raising awareness of emotions (e.g., learning emotions theories), developing skills to manage emotions (e.g., attention deployment, cognitive changes, response modification), and facilitating parent-child relationship (e.g., gratitude). For children, the main topics are similar to that in parents' intervention. In this arm, we give more specific examples and simple explanations to the children.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information provision
Description: Information provision arm will provide the parents and children with four 2-hour weekly sessions. For the parents, the main topics in these four sessions include learning the general information about Hong Kong such as education and medical care, housing condition, employment and training. For children, the main topics include learning the general information about Hong Kong, such as education, community facility, and learning method.
Study: NCT05618678

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DIGNITY
Description: DIGNITY is a multi-component, multi-level intervention that guides shared decision-making in nursing homes to support person-centered dementia care. Based in theory, this intervention targets nursing home staff attitudes and behaviors around assessing and judging whether to engage in risk situations to support resident preferences for everyday living and care despite cognitive decline due to dementia. It includes a protocol manual, baseline training on how to implement the DIGNITY strategy, and six ECHO sessions to help frontline staff negotiate intrinsic and cultural factors in preference situations that carry a risk to residents' health and safety.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Infection Control
Description: This is an attention control intervention with similar dose of educational content and attention from interventionist. It includes distribution of links to the CDC Infection Control Practice Guidelines for nursing homes, a baseline training on infection control practices for frontline workers, and six ECHO coaching sessions.
Study: NCT05667246

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Decaffeinated Coffee
Description: Subjects would be randomized to a group Decaffeinated and subjects will be no caffeine in decaffeinated coffee.
Study: NCT04938206

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The Clinical Decision Rule
Description: The Clinical Decision Rule will be applied to all patients included in the study at different times depending on the type of cancer: at H12-H24 of admission for patients with solid tumor; at H24-H48 for patients with hematological cancer. Patients classified as being at low risk of severe infection by the DRC were then randomized to a control group under standard management or to an experimental group with therapeutic relief. Treatment reduction for the experimental group was started immediately after randomization, in hospital. Discharge was proposed 24 hours later, with follow-up every two days, by telephone or in
Study: NCT05369975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imlifidase
Description: Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly selective towards IgG. The cleavage of IgG generates one F(ab')2- and one homodimeric Fc-fragment and efficiently neutralizes Fc-mediated activities of IgG.

Intervention type: OTHER
Group type: OTHER
Intervention: Normal Transplantation Routine
Description: Transplantation and pre- and post-transplantation therapies in accordance with the clinic's normal transplantation routine.
Study: NCT04938206

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: The Clinical Decision Rule
Description: The Clinical Decision Rule will be applied to all patients included in the study at different times depending on the type of cancer: at H12-H24 of admission for patients with solid tumor; at H24-H48 for patients with hematological cancer. Patients classified as being at low risk of severe infection by the DRC were then randomized to a control group under standard management or to an experimental group with therapeutic relief. Treatment reduction for the experimental group was started immediately after randomization, in hospital. Discharge was proposed 24 hours later, with follow-up every two days, by telephone or in
Study: NCT05369975

Intervention type: OTHER
Group type: OTHER
Intervention: Normal Transplantation Routine
Description: Transplantation and pre- and post-transplantation therapies in accordance with the clinic's normal transplantation routine.
Study: NCT06414434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTX-A51
Description: Multi-kinase inhibitor, 1.0 mg, 2.0 mg, and 7.0 mg immediate-release capsules, taken orally per protocol.
Study: NCT05758337

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibropneumostimulation
Description: New vibrators and techniques of vibropneumostimulation of periimplant tissues have been developed, which will allow us to develop a new concept of the relationship of bone remodulation processes around implants of various designs.
Study: NCT04890171

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic submucosal dissection
Description: Endoscopic submucosal dissection by a endoscopist using endoscopic devices

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Gastrectomy with lymph node dissection by a surgeon
Study: NCT06350279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK39297
Description: 50-600mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK39297
Description: 50-600mg
Study: NCT05135390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK21542
Description: three times per week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: three times per week
Study: NCT04550845

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Focus group analyses
Description: Focus group audiotapes will be transcribed verbatim, and then entered into the qualitative data software package, NVivo 14 for analysis.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Focus group analyses
Description: Focus group audiotapes will be transcribed verbatim, and then entered into the qualitative data software package, NVivo 14 for analysis.
Study: NCT05660083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-NMMA
Description: Patients with HER2 negative metastatic or locally advanced MpBC, will receive a combination of an iNOS inhibitor, nab-paclitaxel and alpelisib . As prophylaxis against deep venous thrombosis and hypertension, patients will receive aspirin (81 mg po daily) and amlodipine (10 mg po Days 0-5 each cycle). Metformin will be initiated at 500 mg once daily starting one week prior to treatment to reduce risk of severe hyperglycemia. Based on tolerability and serial blood sugar assessments, metformin dose will be increased to 500 mg twice daily, followed by 500 mg with breakfast and 1000 mg with dinner, followed by further increase to 1000 mg twice daily if needed. Insulin sensitizers and/or SGLT2i will be used as second anti-diabetic agents, if necessary. For prophylaxis of alpelisib rash, patients will be treated with an anti-histamine (cetirizine 10 mg daily) along with alpelisib.
Study: NCT05051189

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl Citrate
Description: Ventilatory response to fentanyl in patients with OSA Specifically: respiratory changes, CO2, RR, TV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl Citrate
Description: Ventilatory response to fentanyl in patients with OSA Specifically: respiratory changes, CO2, RR, TV
Study: NCT05151978

Intervention type: DIAGNOSTIC_TEST
Intervention: Transcranial Doppler
Description: Transcranial Doppler on middle cerebral arteries

Intervention type: DIAGNOSTIC_TEST
Intervention: Transcranial Doppler
Description: Transcranial Doppler on middle cerebral arteries
Study: NCT05262920

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The BSM Intervention
Description: The BSM intervention entailed a daily electronic journal for monitoring BF and BNP with feedings, bi-weekly texting for 6 weeks from a research nurse for informational support and to promote personalized goal-setting and problem-solving, and hyperlinks to eight uniform BNP educational modules (knowledge and skills) and online resources. 1. Fundamentals of BF (FBF), 2. Deep breathing (DB), 3. BNP non-pharmacological strategies (BNPS), 4. Guided imagery (GI), 5. Pain neurophysiology specifically related to BF (PN-BF), 6. Catastrophizing, 7. Stress reactivity, and 8. Common pumping issues and interventions (CPI).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: The Attention Control and Intervention groups both receive fourth-trimester care videos. The educational modules are the following: Urgent maternal warning signs, caring for the maternal body after birth; infant care; COVID-19 and infant health prevention; maternal and infant immunization; infant safety in the home; maternal and infant dietary recommendations; and national and health resources to support BF in the workplace
Study: NCT06202547

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intra-ovarian injection of bone marrow mesenchymal stromal cells-derived extracellular vesicles
Description: he patient is anesthetized and placed in a lithotomy position, after preparing and washing the vagina with normal saline, under transvaginal ultrasound guidance (Aloka-40000 vaginal probe, Japan) using needle puncture (Reproline medical Gmbh, Rheinbach/Germany). The injection of 2 ml of extracellular vesicles derived from MSCs (equivalent to 30 million cells) will be performed into one ovary of the patient (the accessible ovary).
Study: NCT05653609

Intervention type: DEVICE
Intervention: Cureety TechCare
Description: Weekly adverse event questionnaires completed by the patients using a digital tool called Cureety
Study: NCT06344949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofol
Description: The sedation before tracheal intubation with Ciprofol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: The sedation before tracheal intubation with Propofol
Study: NCT05591378

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: core stability exercises
Description: exercises for 8 weeks and 3 individual sessions per week for 30-45 minutes. Each exercise will be given for 3 to 5 minuts.~first week:Cat camel stretch, all fours stretch and lifting one leg, cobra pose, lying on your back and raising the legs/one leg, and hamstring stretch on chair second week:Straight Leg Crunch, with first week exercises third week:Crunch, bridge exercise,and lifting the legs/one leg straight out with first week exercises fourth week:lifting the legs/one leg to the opposite hand, with first week exercises fifth week:Reverse Crunch, bridge exercise without support with first week exercises sixth week:Hamstring stretch on the Floor with first week exercises seventh week:lifting one hand and one leg, with first week exercises eight week:Exercise Ball Crunch,and stability ball bridge with first week exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: otago exercises
Description: exercises for 8 weeks and 3 individual sessions per week for 30-45 minutes. Each exercise will be given for 3 to 5 minuts.~Walking forward with support, standing on heel with support, side walking with support, standing on one foot with support.Walking forward without support, standing on heel without support, side walking without support, standing on one foot without support.~Walking backward with support, walking on heel with support, walking and turning around, walking on heel with support.~Walking backward without support, walking on heel without support, walking and turning around, walking on heel without
Study: NCT05016674

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LipoLife system
Description: Abdominal Laser-Assisted Liposuction
Study: NCT06512116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIBP-A17
Description: Strength: 1, 2, 4, 5, 6 or 8 mg. Intravenous infusion administration, with a treatment cycle of every 21 days, administered once on the first day of each cycle.~The dose escalation stage, 1mg/kg and 2mg/kg were subjected to accelerated titration, where the safety was evaluated within 21 days after the first administration to one subject. If dose-limiting toxicity (DLT) occurred, the traditional 3+3 dose escalation method was immediately switched. If DLT does not occur, the next dose group will be explored, and the dose exploration starting from 4mg/kg will adopt a 3+3 dose escalation design.
Study: NCT04815707

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Occcult hernia repair
Description: The occult hernia will be repaired during the same inguinal hernia repair
Study: NCT06134427

Intervention type: OTHER
Group type: OTHER
Intervention: basic combat training (investigator did not design the intervention)
Description: 12 weeks basic combat training is 12 weeks is a compulsory program for all cadets accepted in republic indonesia defense university
Study: NCT05521269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANX1502
Description: ANX1502 is a prodrug of ANX1439.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANX1502
Description: ANX1502 is a prodrug of ANX1439.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo comparator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo comparator.
Study: NCT05285813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vibecotamab
Description: Given by vein (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vibecotamab
Description: Given by vein (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given by vein (IV) over about 60 minutes before the dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given by vein (IV) over about 60 minutes before the dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Given by mouth (PO) about 30-60 minutes before the dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Given by mouth (PO) about 30-60 minutes before the dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Given by mouth (PO) or Given by vein (IV) about 30-60 minutes before the dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Given by mouth (PO) or Given by vein (IV) about 30-60 minutes before the dose
Study: NCT04013802

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HLA-matched VSTs
Description: An alternative approach that bypasses the need to grow VSTs for individual patients is to bank closely HLA-matched allogeneic VSTs that could be available as an off the shelf product.~The HLA-matched VST product is to produce immune activity to CMV, Adv, BK virus and EBV in all recipients.~Most recently our group extended this off the shelf approach to five viruses using the T cell product manufactured in 10 days. The VSTs were administered to 38 patients with 45 infections in a phase II clinical trial. A single infusion produced a cumulative complete or partial response rate of 92% overall and the following rates by virus: 100% for BKV (n = 16), 94% for CMV (n = 17), 71% for AdV (n = 7), 100% for EBV (n = 2), and 67% for HHV-6 (human herpesvirus) (n = 3).
Study: NCT06458400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegileridine
Description: single dose+PCA dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oliceridine
Description: single dose+PCA dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: single dose+PCA dose
Study: NCT05429827

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Inject 2 ml normal saline into a myofascial trigger point and evaluate the clinical effects before and after the injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextrose 5% in water
Description: Inject 2 ml 5% dextrose into a myofascial trigger point and evaluate the clinical effects before and after the injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextrose 15% in water
Description: Inject 2 ml 15% dextrose into a myofascial trigger point and evaluate the clinical effects before and after the injection.
Study: NCT03915327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous iron isomaltose anhydride
Description: Enrolled subjects would receive intravenous iron isomaltose anhydride within 24 hours of the subject's inclusion.